Aligos Therapeutics Faces Nasdaq Delisting Warning
Ticker: ALGS · Form: 8-K · Filed: May 22, 2024 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: ALGS
TL;DR
Nasdaq's threatening to delist ALGS, deadline May 27th to fix it.
AI Summary
Aligos Therapeutics, Inc. announced on May 21, 2024, that it received a notice from The Nasdaq Stock Market indicating non-compliance with listing rules. The company has until May 27, 2024, to regain compliance or request a hearing. This follows a prior notice on April 29, 2024, regarding minimum bid price requirements.
Why It Matters
Failure to regain Nasdaq compliance could lead to the company's stock being delisted, significantly impacting its liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company is at high risk of delisting from Nasdaq due to repeated non-compliance with listing rules, which could severely impact its stock value and trading.
Key Numbers
- May 27, 2024 — Compliance Deadline (The company must regain compliance with Nasdaq listing rules by this date.)
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Listing Exchange
- May 21, 2024 (date) — Date of notice
- May 27, 2024 (date) — Deadline for compliance
- April 29, 2024 (date) — Date of prior notice
FAQ
What specific Nasdaq listing rule(s) is Aligos Therapeutics currently non-compliant with?
The filing indicates non-compliance with Nasdaq listing rules, referencing a prior notice on April 29, 2024, regarding the minimum bid price requirement.
What is the deadline for Aligos Therapeutics to regain compliance with Nasdaq listing rules?
The company has until May 27, 2024, to regain compliance or request a hearing.
What actions can Aligos Therapeutics take if it cannot regain compliance by the deadline?
The company can request a hearing with the Nasdaq Hearings Department to present its plan to regain compliance.
Has Aligos Therapeutics received previous notices of non-compliance from Nasdaq?
Yes, the filing mentions a prior notice received on April 29, 2024, concerning the minimum bid price requirement.
What is the potential consequence if Aligos Therapeutics fails to regain compliance?
If the company fails to regain compliance, its securities may be delisted from The Nasdaq Stock Market.
Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-22 16:02:52
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
Filing Documents
- d840680d8k.htm (8-K) — 25KB
- 0001193125-24-144929.txt ( ) — 147KB
- algs-20240521.xsd (EX-101.SCH) — 3KB
- algs-20240521_lab.xml (EX-101.LAB) — 18KB
- algs-20240521_pre.xml (EX-101.PRE) — 11KB
- d840680d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: May 22, 2024 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Financial Officer